News
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Lonza and Vertex sign a long-term commercial supply agreement for CASGEVY® cell therapy based on CRISPR/Cas9 gene-editing technology. Lonza to manufacture at Geleen, NL facility approved by FDA, EMA, and MHRA -
-